Shuttle Pharmaceuticals: Funding, Investors & Team (Sep 2026)
Shuttle Pharmaceuticals, a clinical-stage pharmaceutical company, is using proprietary technology to create new therapies aimed at improving cancer treatment. The company is focused on enhancing the benefits of cancer treatments by utilizing insights from key aspects of cancer therapy, including surgery, radiation therapy, chemotherapy, and immunotherapy. Among the various cancer therapies being developed, radiation therapy (RT) is considered one of the most effective and proven approaches to treating cancer.
Shuttle Pharmaceuticals has raised $35.6M across 7 funding rounds on record, the most recent an undisclosed round of $11.0M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Shuttle Pharmaceuticals Company Profile and Key Stats
Latest funding round on record: May 2026.
Shuttle Pharmaceuticals Funding Rounds
Shuttle Pharmaceuticals raised $4.0M in an undisclosed round announced in Jan 2023.
1.8 years later, an undisclosed round of $4.5M was announced in Oct 2024.
5 months later, an undisclosed round of $5.8M was announced in Mar 2025.
3 months later, an undisclosed round of $4.3M was announced in Jun 2025.
5 months later, an undisclosed round of $2.5M was announced in Nov 2025.
4 months later, an undisclosed round of $3.5M was announced in Mar 2026.
2 months later, an undisclosed round of $11.0M was announced in May 2026.
Shuttle Pharmaceuticals Founders and Leadership Team
Contact details for the Shuttle Pharmaceuticals team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Shuttle Pharmaceuticals Funding Compared to Other Biotechnology Startups
Shuttle Pharmaceuticals' latest round of $11.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Shuttle Pharmaceuticals in Biotechnology and Rockville
Companies Similar to Shuttle Pharmaceuticals
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Shuttle Pharmaceuticals Funding FAQs
What does Shuttle Pharmaceuticals do?
Shuttle Pharmaceuticals, a clinical-stage pharmaceutical company, is using proprietary technology to create new therapies aimed at improving cancer treatment. The company is focused on enhancing the benefits of cancer treatments by utilizing insights from key aspects of cancer therapy, including surgery, radiation therapy, chemotherapy, and immunotherapy. Among the various cancer therapies being developed, radiation therapy (RT) is considered one of the most effective and proven approaches to treating cancer.
How much funding has Shuttle Pharmaceuticals raised?
Shuttle Pharmaceuticals has raised $35.6M across 7 rounds on record. The most recent is an undisclosed round of $11.0M announced in May 2026.
When did Shuttle Pharmaceuticals last raise funding?
Shuttle Pharmaceuticals' most recent funding round on record is an undisclosed round of $11.0M, announced in May 2026.
Who founded Shuttle Pharmaceuticals?
FundedIQ lists Anatoly Dritschilo (Founder), Peter Dritschilo (Founder) at Shuttle Pharmaceuticals.
Where is Shuttle Pharmaceuticals headquartered?
Shuttle Pharmaceuticals is based in Rockville, Maryland, United States.
How many employees does Shuttle Pharmaceuticals have?
Shuttle Pharmaceuticals is in the 11-50 employee band.
How does Shuttle Pharmaceuticals' funding compare to other Biotechnology startups?
Shuttle Pharmaceuticals' latest round of $11.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Shuttle Pharmaceuticals Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Shuttle Pharmaceuticals is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.